Smith & Nephew plc (SNN)
Automate Your Wheel Strategy on SNN
With Tiblio's Option Bot, you can configure your own wheel strategy including SNN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNN
- Rev/Share 6.6514
- Book/Share 6.0274
- PB 2.4023
- Debt/Equity 0.6308
- CurrentRatio 2.8877
- ROIC 0.0612
- MktCap 12670405440.0
- FreeCF/Share 0.6938
- PFCF 20.9083
- PE 30.6999
- Debt/Assets 0.3207
- DivYield 0.0259
- ROE 0.0787
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SNN | HSBC Securities | Buy | Hold | -- | -- | April 25, 2025 |
| Downgrade | SNN | UBS | Buy | Neutral | -- | -- | March 12, 2025 |
News
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA).
Read More
Smith & Nephew shares jump 7% on better-than-expected quarterly growth
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
Smith & Nephew PLC (LSE:SN) rose as much as 7% in afternoon trading on Wednesday after the medical technology group reported stronger-than-expected revenue growth in the first quarter of 2025. The London-listed company posted underlying revenue growth of 3.1% in the three months to March, ahead market consensus of 1.9%.
Read More
Smith & Nephew jumps as hip and knee replacements in demand
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year.
Read More
New Strong Buy Stocks for April 29th
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
MATX, SNN, ALEX, PCB and LTH have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2025.
Read More
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Read More
Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Read More
New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
Published: March 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew's proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period for total hip arthroplasty (THA).1
Read More
Smith & Nephew sees turnaround plan kicking in as profit grows
Published: February 25, 2025 by: Proactive Investors
Sentiment: Positive
Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion.
Read More
UK's Smith+Nephew beats annual profit expectations
Published: February 25, 2025 by: Reuters
Sentiment: Positive
Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset the impact of weak demand from China.
Read More
Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand
Published: February 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair
Read More
About Smith & Nephew plc (SNN)
- IPO Date 1999-11-16
- Website https://www.smith-nephew.com
- Industry Medical - Devices
- CEO Dr. Deepak S. Nath Ph.D.
- Employees 17349